{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-077613","form_type":"8-K","ticker":"KRRO","cik":"0001703647","company_name":"Korro Bio, Inc.","filed_at":"2024-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.177145+00:00","generated_at":"2026-06-04T07:56:44.779338+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Korro Bio reports FY 2023 net loss of $81.2M; cash of $166.1M funds operations into 2026","bullets":["Net loss of $81.2M in 2023 vs. $58.0M in 2022; R&D expenses $57.2M (up from $42.2M).","Cash and short-term investments $166.1M as of Dec 31, 2023, compared to $55.2M at end of 2022.","Regulatory filing for KRRO-110 in Alpha-1 Antitrypsin Deficiency on track for H2 2024.","Preclinical data showed >50% editing using GalNAc conjugates with subcutaneous administration in mice.","Cash runway into 2026; interim clinical readout for KRRO-110 expected in H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-077613","json":"https://secwatch.observer/filing/0001193125-24-077613.json","markdown":"https://secwatch.observer/filing/0001193125-24-077613.md","text":"https://secwatch.observer/filing/0001193125-24-077613.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703647/000119312524077613/0001193125-24-077613-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703647/000119312524077613/d812258d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T07:56:44.779338+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b1c0880461f1aa33a121c77477c9c6f78e3d4713","claim":"Korro Bio, Inc. reported the year ended December 31, 2023 results: net income $81.2 million.","evidence_excerpt":"Korro’s net loss was $81.2 million for the year ended December 31, 2023, as compared to $58.0 million for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312524077613/0001193125-24-077613-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Net income","value":"$81.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}